Therefore, this study hypothesized that the increase in CXCR3+ T cells in the blood of treatment-resistant patients might be caused by a decrease in the activation of CXCL9 and CXCL10 inside the tumor microenvironment. The gene discussed is CXCR3; the disease is neoplasm.